Abstract
Dyslexia is a learning difficulty with neurodevelopmental origins, manifesting as reduced accuracy and speed in reading and spelling despite adequate education. Dyslexia is substantially heritable and frequently co-occurs with other neurodevelopmental conditions, particularly attention deficit-hyperactivity disorder (ADHD). The purpose of this paper was to elucidate how genetic factors predisposing to dyslexia correlate with risk for other neurodevelopmental and psychiatric traits. A large-scale genome-wide association study (GWAS) of dyslexia diagnosis self-report (51,800 cases and ∼1.1 million controls), together with GWAS of ADHD, autism, Tourette syndrome, anxiety, depression, schizophrenia, bipolar, obsessive compulsive disorder, anorexia, were analysed using Genomic Structural Equation Modelling (GenomicSEM) to construct a genomic structural model. The final model consisted of five correlated latent genomic factors described as F1) internalising disorders, F2) psychotic disorders, F3) compulsive disorders, F4) neurodevelopmental conditions, and F5) attention and learning difficulties, which includes ADHD and dyslexia. This latent factor was moderately correlated with internalising disorders (.40) and, to a lesser extent, with neurodevelopmental conditions (.25) and psychotic disorders (.17), and negatively with compulsive disorders (-.16). Unlike ADHD, most of the genomic variance in dyslexia was unique, suggesting a more peripheral relation to psychiatric traits. We further investigated genetic variants underlying both dyslexia and ADHD. This implicated 49 loci (40 of which were not reported in GWAS of the individual traits) mapping to 174 genes (121 not found in GWAS of individual traits). Our study has discovered novel pleiotropic variants and confirms via GenomicSEM the heightened genetic relation between dyslexia and ADHD versus other psychiatric traits. In future, analyses including additional co-occurring traits such as dyscalculia and dyspraxia, for which there are currently no large-scale GWAS, will allow a more clear definition of the attention and learning difficulties genomic factor, yielding further insights into factor structure and pleiotropic effects.
Competing Interest Statement
Pierre Fontanillas and the 23andMe Research Team members are employed by and hold stock or stock options in 23andMe, Inc. All other authors declare no conflicts of interest.
Funding Statement
AC is funded by the Wellcome Trust [218493/Z/19/Z]. HSM is supported by the Biotechnology and Biological Sciences Research Council [BB/T000813/1]. SEF is supported by the Max Planck Society (Germany).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Note that 23andMe participants provided informed consent and volunteered to participate in the research online, under a protocol approved by the external AAHRPP-accredited IRB, Ethical & Independent (E&I) Review Services. As of 2022, E&I Review Services is part of Salus IRB (https://www.versiticlinicaltrials.org/salusirb).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The full GWAS summary statistics for the 23andMe discovery data set will be made available through 23andMe to qualified researchers under an agreement with 23andMe that protects the privacy of the 23andMe participants. Datasets will be made available at no cost for academic use. Please visit https://research.23andme.com/collaborate/#dataset-access/ for more information and to apply to access the data.
